Treatment of Enteric Fever in Pediatric Patients

Empiric Treatment Approach

The Infectious Diseases Society of America recommends starting empiric antimicrobial therapy immediately in pediatric patients with clinical features of sepsis, recent international travel with body temperature ≥38.5°C and/or signs of sepsis, or severe systemic illness with suspected enteric fever 1, 2
The American Academy of Pediatrics suggests obtaining blood, stool, and urine cultures before initiating antibiotics, but emphasizes not to delay treatment while awaiting results 1, 2
Ceftriaxone is the preferred empiric agent for pediatric enteric fever, particularly important for infants <3 months of age and when neurologic involvement is present 1, 2

The Infectious Diseases Society of America recommends narrowing antimicrobial therapy based on susceptibility testing results, which is a strong recommendation with high-quality evidence 1, 2
If isolate unavailable but clinical suspicion remains, the American Academy of Pediatrics suggests tailoring choice to susceptibility patterns from the acquisition setting 1, 2

The Infectious Diseases Society of America advises against using antibiotics for STEC O157 or Shiga toxin-producing E. coli, as this increases risk of hemolytic uremic syndrome 1, 2, 3
The American Academy of Pediatrics recommends not withholding empiric therapy in septic-appearing children while awaiting culture results, as early treatment improves outcomes and reduces mortality 2
The Infectious Diseases Society of America suggests not using fluoroquinolones as first-line in children due to musculoskeletal concerns and widespread resistance, particularly in South Asian strains 3